δ- and μ-opioid receptor mobilization of intracellular calcium in SH-SY5Y human neuroblastoma cells

British Journal of Pharmacology

Volumn 117, Issue 2, 1996, Pages 333-340

  Connor, Mark ^a   Henderson, Graeme ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Calcium mobilization; Intracellular calcium; Muscarinic receptors; Opioids; SH SY5Y

Indexed keywords

1 (5 ISOQUINOLINESULFONYL) 2 METHYLPIPERAZINE; ATROPINE; CALCIUM ION; CARBACHOL; CHOLINERGIC RECEPTOR STIMULATING AGENT; DELTA OPIATE RECEPTOR; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; ENKEPHALIN[2,5 DEXTRO PENICILLAMINE]; MAITOTOXIN; MECAMYLAMINE; MU OPIATE RECEPTOR; MUSCARINIC RECEPTOR; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; NALTRINDOLE; NICOTINIC RECEPTOR BLOCKING AGENT; OPIATE AGONIST; OPIATE ANTAGONIST; PERTUSSIS TOXIN; PROTEIN KINASE INHIBITOR; THAPSIGARGIN;

ARTICLE; CALCIUM CELL LEVEL; CALCIUM MOBILIZATION; CANCER CELL CULTURE; DRUG INHIBITION; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; PRIORITY JOURNAL;

EID: 0029671036     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1476-5381.1996.tb15195.x     Document Type: Article

References (39)

1. CHEN, L. & HUANG, L-Y M. (1991). Sustained potentiation of NMDA-mediated glutamate responses through activation of protein kinase C by a μ opioid. Neuron, 7, 319-326.
2. CHIJIWA, T., MISHIMA, A., HAGIWARA, M., SANO, M., HAYASHI, K., INOUE, T., NAITO, K., TOSHIOKA, T. & HIDAKA, H. (1990). Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells. J. Biol. Chem., 265, 5267-5273.
3. COLLIER, H.O.J. & ROY, A.C. (1974). Morphine-like drugs inhibit the stimulation by E prostaglandins of cyclic AMP formation by rat brain homogenate. Nature, 248, 24-27.
4. CONNOR, M.A. & HENDERSON, G. (1994). Opioids mobilize intracellular calcium in SH-SY5Y cells. Br. J. Pharmacol., 113, 16P.
5. CONNOR, M.A., KEIR, M.J. & HENDERSON, G. (1995). δ-Opioid receptor mobilization of intracellular calcium in SH-SY5Y cells: lack of evidence for receptor subtypes. Analgesia, (in press).
6. CONNOR, M.A., PLANNER, A. & HENDERSON, G. (1994). δ and μ Opioid mobilization of calcium in neuroblastoma cells. Regul. Pept., 54, 65-66.
7. 2+ channels. Neuroscience, 54, 401-407.
8. EXTON, J.H. (1994). Phosphoinsoitide phospholipases and G proteins in hormone action. Annu. Rev. Physiol., 56, 349-369.
9. 2+ indicators with greatly improved fluorescence properties. J. Biol. Chem., 260, 3440-3450.
10. GUCKER, S. & BIDLACK, J.M. (1992). Protein kinase C activation increases the rate and magnitude of agonist-induced δ-opioid receptor down-regulation in NG108-15 cells. Mol. Pharmacol., 42, 656-665.
11. HIDAKA, H., INAGAKI, M., KAWAMOTO, S & SASAKI, Y. (1984). Isoquinolinesulfonamides, novel and potent inhibitors of cyclic nucleotide dependent protein kinase and protein kinase C. Biochemistry, 23, 5036-5041.
12. JIN, W., LEE, N.M., LOH, H.H. & THAYER, S.A. (1993). Dual excitatory and inhibitory effects of opioids on intracellular calcium in neuroblastoma x glioma hybrid NG108-15 cells. Mol. Pharmacol., 42, 1083-1089.
13. JIN, W., LEE, N.M., LOH, H.H. & THAYER, S.A. (1994). Opioids mobilize calcium from inositol 1,4,5-trisphosphate-sensitive stores in NG108-15 cells. J. Neurosci., 14, 1920-1929.
14. KAZMI, S.M.I. & MISHRA, R.K. (1986). Opioid receptors in human neuroblastoma SH-SY5Y cells: evidence for distinct morphine (μ) and enkephalin (δ) binding sites. Biochem. Biophys. Res. Commun., 173, 813-820.
15. KAZMI, S.M.I. & MISHRA, R.K. (1987). Comparative pharmacological properties and functional coupling of μ and δ opioid receptor sites in human neuroblastoma SH-SY5Y cells. Mol. Pharmacol., 32, 109-118.
16. LAUGWITZ, K-L., OFFERMAN, S.S., SPICHER, K. & SCHULTZ, G. (1993). μ and δ Opioid receptors differentially couple to G protein subtypes in membranes of human neuroblastoma SH-SY5Y cells. Neuron., 10, 233-242.
17. 2+ and inositol 1,4,5-trisphosphate mass in a human neuroblastoma cell line, SH-SY5Y. Biochem. J., 265, 555-562.
18. NORTH, R.A. (1993). Opioid Actions on Membrane Ion Channels. In Opioids I, ed. Herz A., pp. 773-797. Berlin, Heidelberg: Springer Verlag.
19. 2+ mobilization between bradykinin and agonists for pertussis toxin-sensitive G-protein coupled receptors in NG108-15 cells. FEBS Lett., 301, 223-226.
20. 2+ system through cross-talk between opioid receptors and P2-purinergic or bradykinin receptors in NG108-15 cells. Biochem. J., 290, 241-247.
21. s-linked neurotransmitter receptors to stimulate adenylyl cyclase activity of rat olfactory bulb. J. Neurochem., 61, 2183-2190.
22. 2+ in response to lysylbradykinin and histamine in a cultured human colonic epithelium. Eur. J. Pharmacol., 199, 77-91.
23. PRATHER, P.L., MCGINN, T.M., ERICKSON, L.J., EVANS, C.J., LOH, H.H. & LEE, P-Y. (1994a). Ability of δ-opioid receptors to interact with multiple G-proteins is independent of receptor density. J. Biol. Chem., 269, 21293-21302.
24. PRATHER, P.L., TSAI, A.W. & LAW, P.L. (1994b). Mu and Delta opioid receptor desensitization in undifferentiated human neuroblastoma SH-SY5Y cells. J. Pharmacol. Exp. Ther., 270, 177-184.
25. SEWARD, E., HAMMOND, C. & HENDERSON, G. (1991). μ-Opioid-receptor-mediated inhibition of the N-type calcium-channel current. Proc. R. Soc. (Series B), 244, 129-135.
26. SEWARD, E.P., HENDERSON, G. & SADEE, W. (1990). Inhibition of calcium currents by μ and δ opioid receptor activation in differentiated human neuroblastoma cells. Adv. Biosci., 75, 181-183.
27. SIMONIN, F., BEFORT, K., GAVERIAUX-RUFF, C., MATTHES, H., NAPPEY, V., LANNES, B., MICHELETTI, G. & KEIFFER, B. (1994). The human δ-opioid receptor: genomic organization, cDNA cloning, functional expression and distribution in human brain. Mol. Pharmacol., 46, 1015-1021.
28. SMART, D., SMITH, G. & LAMBERT, D.G. (1994). μ-Opioid receptor stimulation of inositol (1,4,5)trisphosphate formation via a pertussis toxin-sensitive G protein. J. Neurochem., 62, 1009-1014.
29. SMART, D., SMITH, G. & LAMBERT, D.G. (1995). μ-Opioids activate phospholipase C in SH-SY5Y human neuroblastoma cells via calcium channel opening. Biochem. J., 305, 577-582.
30. 2-enkephalinamide and opiate-sensitive adenylate cyclase on human neuroblastoma (SH-SY5Y) cells. Anal. N.Y. Acad. Sci., 435, 205-207.
31. SOERGEL, D.G., YASUMOTO, T., DALY, J.W. & GUSOVSKY, F. (1992). Maitotoxin effects are blocked by SK&F 96365, an inhibitor of receptor-mediated calcium entry. Mol. Pharmacol., 41, 487-493.
32. SUPATTAPONE, S., DANOFF, S.K., THEIBERT, A., JOSEPH, S.K., STEINER, J. & SNYDER, S.H. (1988). Cyclic AMP-dependent phosphorylation of a brain inositol trisphosphate receptor decreases its release of calcium. Proc. Natl. Acad. Sci. U.S.A., 85, 8747-8750.
33. TANG, T., KIANG, J.G. & COX, B.M. (1994). Opioids acting through delta receptors elicit a transient increase in the intracellular free calcium concentration in dorsal root ganglion-neuroblastoma hybrid ND8-47 cells. J. Pharmacol. Exp. Ther., 270, 40-46.
34. TANG, W-J. & GILMAN, A.G. (1991). Type specific regulation of adenylyl cyclase by G protein βγ subunits. Science, 254, 1500-1503.
35. 2+-ATPase. Proc. Natl. Acad. Sci. U.S.A., 87, 2466-2470.
36. 2+ mobilization in single cells of bradykinin-sensitized differentiated neuroblastoma hybridoma (NG108-15) cells. Neurosci. Lett., 148, 93-96.
37. TOULLEC, D., PIANETTI, P., COSTE, H., BELLEVERGUE, P., GRANDPERRET, T., AJAKANE, M., BAUDET, V., BOISSIN, P., BOURSIER, E., LORIOLLF, F., DUHAMEL, L., CHARON, D. & KIRILOVSKY, J. (1991). The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. J. Biol. Chem., 266, 15771-15871.
38. WOJCIKIEWICZ, R.J.H., TOBIN, A.B. & NAHORSKI, S.R. (1994). Desensitization of cell signalling mediated by phosphoinositidase C. Trends Pharmacol. Sci., 14, 279-285.
39. YU, V.C. & SADEE, W. (1988). Efficacy and tolerance of narcotic analgesics at the mu opioid receptor in differentiated human neuroblastoma cells. J. Pharmacol. Exp. Ther., 245, 350-355.